Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the aging population. Hence, quality healthcare stocks, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK), might be worth looking into. Read more….

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

StockNews.com

Stock Market Today: Semis Get Slammed and Blue Chips Bounce

The potential for more curbs on tech sales to China set off a rotation into blue chips.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Blue-Chip Stocks to Buy and Hold Forever

Amidst market uncertainty, blue-chip stocks provide stability, diversification, and reliable returns. Therefore, Johnson & Johnson (JNJ), International Business Machines (IBM), and AT&T (T) could be wise picks to buy and hold forever for smart investors. Read on.

StockNews.com

Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is expected to release its second-quarter earnings next week, and analysts project a low single-digit profit dip.

Barchart

3 Healthcare Stocks With Strong Profit Margins to Buy Now

The healthcare industry is poised to grow rapidly due to the rising need for medical aid, government initiatives, and increasing chronic diseases contributing to overall stability. Given the industry’s promising prospects, investors could consider buying quality healthcare stocks: UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and AbbVie (ABBV), with strong…

StockNews.com

3 Blue-Chip Stocks Offering Stability

Blue-chip companies, characterized by large capitalization, global footprint, solid financial performance, robust balance sheet, and dominant market position, are favored by investors seeking stability and long-term growth potential. Thus, quality blue-chip stocks Microsoft (MSFT), Procter & Gamble (PG), and Johnson & Johnson (JNJ) could be attractive buys for steady returns.…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

How Is Johnson & Johnson's Stock Performance Compared to Other Pharmaceutical Stocks?

Johnson & Johnson has recently underperformed other pharmaceutical stocks. However, Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Top 4 Pharma Stocks for Long-Term Value Investors in 2024

The pharmaceutical sector is experiencing rapid growth thanks to the rising demand for precision drugs, the growing geriatric population, and an uptick in chronic diseases. Given this backdrop, long-term value investors could consider buying and holding quality pharmaceutical stocks such as Organon (OGN), Procaps (PROC), Johnson & Johnson (JNJ), and…

StockNews.com

Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

As Johnson & Johnson trails the broader market, Wall Street analysts remain cautiously optimistic about the stock's prospects.

Barchart

Analyst updates Johnson & Johnson stock price target after earnings

This is what could happen next to Johnson & Johnson shares.

The Street

JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up?

As pharma titan Johnson & Johnson (JNJ) gears up to unveil its first-quarter results on April 16, 2024, anticipation looms over the pharmaceutical industry. JNJ’s recent acquisitions signal the company’s strategic expansions, and given its history as one of the prominent pharma companies, is JNJ’s forecast as stunning? Let us…

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

Johnson & Johnson Poised For Growth Despite Recent Challenges

Johnson & Johnson (NYSE: JNJ) poised for growth despite challenges, with analysts estimating a 10% upside. Resilient in market fluctuations, key drivers in...

Top News

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Pharma Titans Making Waves in Wall Street

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

StockNews.com

3 Pharma Stocks With Prescription for Stability and Value in March

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

Barchart

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

StockNews.com

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

Investors Business Daily

J&J Flashes A Sell Signal Despite A MedTech Beat That Bodes Well For Its Rivals

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. But JNJ stock toppled.

StockNews.com

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

StockNews.com

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Barchart

2 Dividend Kings Yielding Around 3% to Grab Now

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

StockNews.com

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

1 2 3 4 5

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.